Suzuken Co Ltd
TSE:9987
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
JP |
Suzuken Co Ltd
TSE:9987
|
346.6B JPY | 4.3 | ||
US |
Mckesson Corp
NYSE:MCK
|
68.8B USD | 31.4 | ||
US |
Cencora Inc
NYSE:COR
|
47.7B USD | 16.1 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 21 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
26.4B USD | 9.3 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.2B USD | 7 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -236.8 | |
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
62B HKD | 7.2 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
55.1B CNY | 41.5 | ||
IT |
Amplifon SpA
MIL:AMP
|
7.1B EUR | 45.9 | ||
CN |
S
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
50.7B CNY | 5.6 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.